Similar articles

• [Early application of angiotensin converting enzyme inhibitors in acute myocardial infarction].

  Ter-Grigorian V, Aĭrapetian G. Ter-Grigorian V, et al. Klin Med (Mosk). 1999;77(7):52-5. Klin Med (Mosk). 1999. PMID: 10483169 Russian.
• Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age.

  Krumholz HM, Vaccarino V, Ellerbeck EF, Kiefe C, Hennen J, Kresowik TF, Gold JA, Jencks SF, Radford MJ. Krumholz HM, et al. Am J Cardiol. 1997 Mar 1;79(5):581-6. doi: 10.1016/s0002-9149(96)00819-3. Am J Cardiol. 1997. PMID: 9068512
• Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.

  Kramer CM, Ferrari VA, Rogers WJ, Theobald TM, Nance ML, Axel L, Reichek N. Kramer CM, et al. J Am Coll Cardiol. 1996 Jan;27(1):211-7. doi: 10.1016/0735-1097(95)00429-7. J Am Coll Cardiol. 1996. PMID: 8522697
• Left ventricular remodeling after acute myocardial infarction.

  Pfeffer MA. Pfeffer MA. Annu Rev Med. 1995;46:455-66. doi: 10.1146/annurev.med.46.1.455. Annu Rev Med. 1995. PMID: 7598478 Review.
• Angiotensin converting enzyme inhibition therapy following myocardial infarction. Rationale for clinical trials.

  Pfeffer MA. Pfeffer MA. Herz. 1991 Sep;16 Spec No 1:278-82. Herz. 1991. PMID: 1840297 Review.